Healthcare provider profile · identity verified

Nancy J Short, MD

Family Practice · EAST MOLINE, IL · NPI 1134125032

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	189	48
Atorvastatin Calcium	Atorvastatin Calcium	182	54
Lisinopril	Lisinopril	150	41
Amlodipine Besylate	Amlodipine Besylate	108	31
Losartan Potassium	Losartan Potassium	88	26
Albuterol Sulfate Hfa	Albuterol Sulfate	73	25
Metoprolol Succinate	Metoprolol Succinate	72	14
Metformin Hcl	Metformin Hcl	71	19
Rosuvastatin Calcium	Rosuvastatin Calcium	69	22
Omeprazole	Omeprazole	68	19
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	55	15
Duloxetine Hcl	Duloxetine Hcl	53	12
Venlafaxine Hcl Er	Venlafaxine Hcl	53	14
Ezetimibe	Ezetimibe	46	17
Farxiga	Dapagliflozin Propanediol	46	13
Pantoprazole Sodium	Pantoprazole Sodium	46	11
Hydrochlorothiazide	Hydrochlorothiazide	39	11
Meclizine Hcl	Meclizine Hcl	37	suppressed
Pravastatin Sodium	Pravastatin Sodium	36	11
Clopidogrel	Clopidogrel Bisulfate	35	suppressed
Allopurinol	Allopurinol	33	suppressed
Ondansetron Odt	Ondansetron	33	suppressed
Gabapentin	Gabapentin	32	11
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	32	suppressed
Tramadol Hcl	Tramadol Hcl	32	suppressed
Ozempic	Semaglutide	30	suppressed
Rybelsus	Semaglutide	30	suppressed
Jardiance	Empagliflozin	29	suppressed
Eliquis	Apixaban	28	suppressed
Trazodone Hcl	Trazodone Hcl	28	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	27	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	27	suppressed
Fluticasone Propionate	Fluticasone Propionate	26	11
Metoprolol Tartrate	Metoprolol Tartrate	26	suppressed
Valsartan	Valsartan	26	suppressed
Simvastatin	Simvastatin	25	suppressed
Linzess	Linaclotide	22	suppressed
Valacyclovir	Valacyclovir Hcl	22	suppressed
Potassium Chloride	Potassium Chloride	21	suppressed
Furosemide	Furosemide	20	suppressed
Humalog Kwikpen U-100	Insulin Lispro	19	suppressed
Spironolactone	Spironolactone	19	suppressed
Famotidine	Famotidine	18	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	18	suppressed
Niacin Er	Niacin	18	suppressed
Sertraline Hcl	Sertraline Hcl	18	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	17	suppressed
Meloxicam	Meloxicam	17	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	17	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	17	suppressed
Arnuity Ellipta	Fluticasone Furoate	16	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	16	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	16	suppressed
Labetalol Hcl	Labetalol Hcl	16	suppressed
Nitroglycerin	Nitroglycerin	16	12
Tretinoin	Tretinoin	16	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	16	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	15	suppressed
Dilantin	Phenytoin Sodium Extended	15	suppressed
Janumet Xr	Sitagliptin Phos/Metformin Hcl	15	suppressed
Metformin Hcl Er	Metformin Hcl	15	suppressed
Ondansetron Hcl	Ondansetron Hcl	15	suppressed
Prednisone	Prednisone	15	suppressed
Raloxifene Hcl	Raloxifene Hcl	15	suppressed
Cephalexin	Cephalexin	14	12
Tamsulosin Hcl	Tamsulosin Hcl	14	suppressed
Tizanidine Hcl	Tizanidine Hcl	14	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	14	suppressed
Atenolol	Atenolol	13	suppressed
Baclofen	Baclofen	13	suppressed
Carvedilol	Carvedilol	13	suppressed
Divalproex Sodium	Divalproex Sodium	13	suppressed
Donepezil Hcl	Donepezil Hcl	13	suppressed
Levemir Flexpen	Insulin Detemir	13	suppressed
Fluvastatin Er	Fluvastatin Sodium	12	suppressed
Glipizide	Glipizide	12	suppressed
Chlorthalidone	Chlorthalidone	11	suppressed
Pregabalin	Pregabalin	11	suppressed
Topiramate	Topiramate	11	suppressed
Tradjenta	Linagliptin	11	suppressed
Ursodiol	Ursodiol	11	suppressed
Xarelto	Rivaroxaban	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error